Insight

Pashtoon Kasi: Privileged and honored to be a part of City of Hope Orange County

Pashtoon Kasi/LinkedIn

Jan 11, 2025, 14:20

Pashtoon Kasi: Privileged and honored to be a part of City of Hope Orange County

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, Orange County, shared a post by City of Hope Orange County on X, adding:

“Privileged and honored to be a part of City of Hope.

Amongst many things:

Providing ‘real-time’ multidisciplinary care.

Option of opening clinical trials within:

90 days = standard
60 days = expedited
45 days = expedited

Come visit us City of Hope Orange County.
Orange County.”

Quoting City of Hope | Orange County’s post:

“Pashtoon Kasi, M.D., medical director of GI oncology, is an expert in cancer genomics and personalized therapies. He’s advancing immunotherapy techniques, such as targeting colorectal cancer “roots up,” and leading groundbreaking research in liquid biopsies and immunotherapy.”

Proceed to the video attached in the post.

Dr. Pashtoon Kasi is the Medical Director of GI Medical Oncology at City of Hope, Orange County. Previously, Dr. Kasi served as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of Iowa, following positions as an Assistant Professor of Medicine and Oncology at both the University of Iowa and Mayo Clinic. He also served as the Director of Colon Cancer Research and Director of Precision Medicine Research for Liquid Biopsies at Weill Cornell Medicine.

His research primarily focuses on “liquid biopsies,” particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Dr. Kasi is also recognized as an author and editor of several significant books, including “Research: What, Why, and How: A Treatise from Researchers to Researchers” and “Impact of Circulating Tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies.”

His scholarly contributions extend to over 100 publications in esteemed peer-reviewed journals. He also received the Yvonne Award 2024 by OncoDaily in the “challenging the status quo” category.